Abiopharma

Clinical trial NCT07712874: start date: 2026-08-27 → 2026-08-30.

Clinical trial NCT07368153 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-02-01 → 2026-08-20

Clinical trial NCT04514367 updates: 1. start date: 2020-08-17 → 2020-09-29 2. completion date: 2022-01-28 → 2022-08-29 3. primary completion date: 2022-01-28 → 2022-08-29

Clinical trial NCT05718219 updates: 1. status: ACTIVE_NOT_RECRUITING → TERMINATED 2. completion date: 2026-12-30 → 2026-04-30 3. primary completion date: 2025-12-30 → 2025-04-30 4. enrollment: 408 → 49 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT03668340 updates: 1. completion date: 2027-07-01 → 2027-09-01 2. primary completion date: 2026-07-01 → 2026-09-01

Clinical trial NCT07626411 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-07-31 → 2026-08-10

Clinical trial NCT02928497: status: COMPLETED → TERMINATED.

Clinical trial NCT07549490: start date: 2026-08-27 → 2026-08-30.

📋 Spellacy Michael (Ex-Board Member) plans to sell 737 shares of Archer Aviation Inc. (at $0.02 each, total $13.27) Filed: Aug 25, 2026 | ID: 000005

Clinical trial NCT07675161 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-12-01 → 2026-08-07 3. primary completion date: 2026-08-01 → 2026-08-07 4. enrollment: 100 → 59 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT04039607: status: ACTIVE_NOT_RECRUITING → COMPLETED.

Clinical trial NCT04876248: primary completion date: 2026-12-01 → 2026-10-21.

Clinical trial NCT04852601 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-05-01 → 2026-05-31 3. enrollment: 41500 → 35403 participants 4. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07365839 updates: 1. start date: 2026-07-01 → 2026-10-01 2. completion date: 2035-02-28 → 2035-05-28 3. primary completion date: 2035-02-28 → 2035-05-28

Clinical trial NCT05460767 updates: 1. status: UNKNOWN → ACTIVE_NOT_RECRUITING 2. completion date: 2024-12-31 → 2027-06-30 3. primary completion date: 2024-03-31 → 2026-12-31 4. enrollment: 260 → 504 participants 5. enrollment type: ESTIMATED → ACTUAL 6. allocation: NA → NON_RANDOMIZED